Biotech Rips In Anticipation Of Q3 Results

Biotech Rips In Anticipation Of Q3 Results

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, November 1, 2022

Certain events bring about volatility that creates massive opportunities for traders on either side of the screen. That’s exactly what happened on Tuesday after a Berlin-based biotech company announced it plans to announce its third quarter 2022 financial results and business update on Thursday, November 10, 2022.

Traders tried to get ahead of this event during Tuesday’s session as shares of ATAI Life Sciences NV (Nasdaq:ATAI) were pushed up to $3.65/share (+23.73%) at the early session high. 

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.


Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Shares on the Rise Following Partnership News With Major Potato Chip Brand
Slowing Growth Increases Hopes of a Rate Cut Pivot in Canada 
Re-Classification of Marijuana Sends Shares of Cannabis Operator on a Tear
Most Popular
FREE Newsletter


Back to Top